The Lipid Disorder Treatment Market is projected to show moderate growth in the next five years

The recent study on the lipid disorder treatment market covers an in-depth analysis of the market on the basis of drug type, distribution channel, and geography. The report also covers the country level analysis within the regions as well. Additionally, the report covers the key trends in the market along with drivers and restraint during the forecast period 2018-2023. According to the report titled “Lipid Disorder Treatment Market – Forecast from 2018 to 2023”, the market is estimated to grow at a moderate pace during the forecast period.

The report has segmented the lipid disorder treatment market by drug type (lovastatin, atorvastatin, rosuvastatin, others), by distribution channel (offline, online) and by geography such as North America (United States, Canada, Mexico, others), South America (Brazil, Argentina, others), Europe (Germany, France, United Kingdom, Spain, others), Middle East and Africa, and Asia Pacific (China, Japan, Korea, India, others). The growing prevalence of cardiovascular disease is increasing the probability of an individual suffering from lipid disorders. In fact, in the United States, more than 12% of adults aged 20 and older had total cholesterol higher than 240 mg/dL, and more than 18% had high-density lipoprotein (HDL, or “good”) cholesterol levels less than 40 mg/dL (source: Centre for Disease Control and Prevention).

Asia Pacific is estimated to grow rapidly during the forecast period.

The growing focus by the government of emerging economies like India, China, and Philippines among others to increase the access to healthcare services to the individuals is expected to drive the Asia Pacific lipid disorder treatment market. Simultaneously, the steady improvement in the health insurance coverage in the region is further anticipated to augment the growth of the market.

Some of the major players discussed in the reports are Ranbaxy Laboratories Ltd, Sun Pharmaceutical Industries Ltd., Merck & Co., and Pfizer Inc. among others.

About Us:

Knowledge Sourcing Intelligence (KSI) is a market research and consulting organization based out of India. KSI publishes research studies spanning across ten industry verticals. KSI has a team of experienced and young professionals with a singular focus on delivering high-quality research services to enterprises, non-government organizations, government agencies, and research institutes and organizations. We publish hundreds of reports per year centring on niche and latest technologies. We engage with key decision makers and stakeholders across the value chain to provide clients with a detailed analysis and bird’s-eye view of the market with whole market dynamics, statistical forecasts, competitive analysis, key trends, market drivers and challenges and strategic recommendations for making informed decisions. Our success lies in the effort of our analysts who strive to meet client expectations by delivering quality work within the stipulated deadlines.

Contact:

Knowledge Sourcing Intelligence LLP
Suite 406, BSI Business Park
H-140, Sector 63, Noida, U.P. – 201301 India
E: [email protected] | P: +1-866-714-4587